Tau oligomers and tau toxicity in neurodegenerative disease.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Biochemical Society Transactions

• Publication date

  2012-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1042/BST20120134PMID 22817713PMCID PMC3704193
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport.

  2012cited by this paper
• Pathogenic Forms of Tau Inhibit Kinesin-Dependent Axonal Transport through a Mechanism Involving Activation of Axonal Phosphotransferases

  2011cited by this paper
• Characterization of Prefibrillar Tau Oligomers in Vitro and in Alzheimer Disease*

  2011cited by this paper
• Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport.

  2011cited by this paper
• Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

  2011cited by this paper
• Heat shock proteins as suppressors of accumulation of toxic prefibrillar intermediates and misfolded proteins in neurodegenerative diseases.

  2010cited by this paper
• Preparation and characterization of neurotoxic tau oligomers.

  2010cited by this paper
• Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport

  2010cited by this paper
• Molecular mechanisms of neurodegeneration in Alzheimer's disease.

  2010cited by this paper
• The amino terminus of tau inhibits kinesin‐dependent axonal transport: Implications for filament toxicity

  2009cited by this paper
• Axonal Transport Defects in Neurodegenerative Diseases

  2009cited by this paper
• Granular tau oligomers as intermediates of tau filaments.

  2007cited by this paper
• Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy

  2007cited by this paper
• Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

  2007cited by this paper
• Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo

  2006cited by this paper
• Global hairpin folding of tau in solution.

  2006cited by this paper
• Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms

  2005cited by this paper
• Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function

  2005cited by this paper
• Infectious disease: Unravelling SARS lethality

  2005cited by this paper
• Tau, tangles, and Alzheimer's disease.

  2005cited by this paper
• Tau phosphorylation in neuronal cell function and dysfunction

  2004cited by this paper
• Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment.

  2003cited by this paper
• Chaperones increase association of tau protein with microtubules

  2003cited by this paper
• Single‐molecule investigation of the interference between kinesin, tau and MAP2c

  2002cited by this paper
• Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles

  2001cited by this paper
• Tau and transgenic animal models.

  2001cited by this paper
• Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment

  2001cited by this paper
• Neurodegenerative tauopathies.

  2001cited by this paper
• Neurons may live for decades with neurofibrillary tangles.

  1999cited by this paper
• A nucleated assembly mechanism of Alzheimer paired helical filaments.

  1998cited by this paper
• Kinesin and dynein superfamily proteins and the mechanism of organelle transport.

  1998cited by this paper
• Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution.

  1998cited by this paper
• The Structural Basis of Monoclonal Antibody Alz50's Selectivity for Alzheimer's Disease Pathology*

  1996cited by this paper
• A monoclonal antibody against kinesin inhibits both anterograde and retrograde fast axonal transport in squid axoplasm.

  1990cited by this paper
• Received

  1868cited by this paper

• Nanoscopic tau aggregates are not shared intermediates but disease-specific entities across tauopathies.

  2026cites this paper
• Tau Oligomerization Drives Neurodegeneration via Nuclear Membrane Invagination and Lamin B Receptor Binding in Alzheimer’s disease

  2025cites this paper
• Biomolecular phase separation of microtubule-associated protein Tau and its role in the genesis of Brain Disorders.

  2025cites this paper
• Computational Insights into the Destabilization of Baicalein on the Tau Protofibrils Associated with Alzheimer' s Disease and Chronic Traumatic Encephalopathy.

  2025cites this paper
• Tau4RD fibril polymorphism is imprinted during early aggregation

  2025cites this paper
• A brain‐derived tau oligomer polymorph is associated with cognitive resilience to Alzheimer's disease

  2025cites this paper
• Functional Analysis of Direct In Vitro Effect of Phosphorylated Tau on Mitochondrial Respiration and Hydrogen Peroxide Production

  2025cites this paper
• Active Immunization: A Novel Therapeutic Strategy for Treating Alzheimer's Disease.

  2025cites this paper
• A Bioinformatic Analysis of BAG Protein Interactors and Pathways in Alzheimer’s and Parkinson’s Disease

  2025cites this paper
• Small tau aggregates exhibit disease-specific molecular profiles across tauopathies

  2025cites this paper
• Selective imaging probes for differential detection of pathological tau polymorphs in tauopathies.

  2025cites this paper
• Novel strategies for targeting tau oligomers in neurodegenerative diseases

  2025cites this paper
• Herpes simplex virus‐1 infection alters microtubule‐associated protein Tau splicing and promotes Tau pathology in neural models of Alzheimer's disease

  2025cites this paper
• Bibliometric analysis of pathological mechanisms in Alzheimer's disease: Applications based on mouse models

  2025cites this paper
• PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications.

  2024cites this paper
• Unraveling the Structure and Dynamics of Ac-PHF6-NH2 Tau Segment Oligomers

  2024cites this paper
• Oligomeric Tau-induced Oxidative Damage and Functional Alterations in Cerebral Endothelial Cells: Role of RhoA/ROCK Signaling Pathway.

  2024cites this paper
• Novel 6-hydroxybenzothiazol-2-carboxamides as potent and selective monoamine oxidase B inhibitors endowed with neuroprotective activity.

  2024cites this paper
• Evidence mapping and quality assessment of systematic reviews on exercise intervention for Alzheimer's disease.

  2024cites this paper
• Paradoxical attenuation of early amyloid-induced cognitive impairment and synaptic plasticity in an aged APP/Tau bigenic rat model

  2024cites this paper
• Distinct regulation of Tau Monomer and aggregate uptake and intracellular accumulation in human neurons

  2024cites this paper
• Fluorescence-Based Monitoring of Early-Stage Aggregation of Amyloid-β, Amylin Peptide, Tau, and α-Synuclein Proteins

  2024cites this paper
• Detecting the Undetectable: Advances in Methods for Identifying Small Tau Aggregates in Neurodegenerative Diseases

  2024cites this paper
• Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against α-synuclein and 2N4R tau

  2024cites this paper
• TGF-β1 signalling in Alzheimer’s pathology and cytoskeletal reorganization: a specialized Tau perspective

  2023cites this paper
• Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.

  2023cites this paper
• Thioflavin S Staining and Amyloid Formation Are Unique to Mixed Tauopathies

  2023cites this paper
• Mitotic phosphorylation of Tau/MAPT modulates cell cycle progression in prostate cancer cells

  2023cites this paper
• Tau-RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change.

  2023cites this paper
• Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations

  2023cites this paper
• Aggregation, Transmission, and Toxicity of the Microtubule-Associated Protein Tau: A Complex Comprehension

  2023cites this paper
• Alzheimer's disease and related tauopathies: disorders of disrupted neuronal identity.

  2023cites this paper
• Neuronal loss and inflammation preceding fibrillary tau pathology in a rat model with early human-like tauopathy.

  2023cites this paper
• The evolution of selective autophagy as a mechanism of oxidative stress response

  2023cites this paper
• An Insight into Cellular and Molecular Mechanisms Underlying the Pathogenesis of Neurodegeneration in Alzheimer’s Disease

  2023cites this paper
• Liquid - liquid phase separation of tau: Driving forces, regulation, and biological implications.

  2023cites this paper
• The Role of Protein-L-isoaspartyl Methyltransferase (PIMT) in the Suppression of Toxicity of the Oligomeric Form of Aβ42, in Addition to the Inhibition of Its Fibrillization.

  2023cites this paper
• DNAzyme-driven tripedal DNA walker triggered hybridization chain reaction for label-free electrochemical detection of Alzheimer’s tau protein

  2023cites this paper
• Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates

  2022cites this paper
• Novel molecular mechanisms in Alzheimer’s disease: The potential role of DEK in disease pathogenesis

  2022cites this paper
• Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets

  2022cites this paper
• Heterogeneous Tau Oligomers as Molecular Targets for Alzheimer’s Disease and Related Tauopathies

  2022cites this paper
• Molecular crowding and RNA synergize to promote phase separation, microtubule interaction, and seeding of Tau condensates

  2022cites this paper
• The current state of amyloidosis therapeutics and the potential role of fluorine in their treatment.

  2022cites this paper
• Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer’s and Parkinson’s Disease

  2022cites this paper
• Prion-like behavior of TDP-43 aggregates and its implication to disease

  2022cites this paper
• Phosphorylation but Not Oligomerization Drives the Accumulation of Tau with Nucleoporin Nup98

  2022cites this paper
• Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease.

  2022cites this paper
• Combined induction of mTOR-dependent and mTOR-independent pathways of autophagy activation as an experimental therapy for Alzheimer's disease-like pathology in a mouse model.

  2022cites this paper
• Tau liquid–liquid phase separation: At the crossroads of tau physiology and tauopathy

  2022cites this paper
• Journal Pre-proof SARS-CoV-2 Infection Increases the Gene Expression Profile for Alzheimer’s Disease Risk

  2022cites this paper
• Journal Pre-proof SARS-CoV-2 Infection Increases the Gene Expression Profile for Alzheimer’s Disease Risk

  2022cites this paper
• Journal Pre-proof SARS-CoV-2 Infection Increases the Gene Expression Profile for Alzheimer’s Disease Risk

  2022cites this paper
• SARS-CoV-2 infection increases the gene expression profile for Alzheimer’s disease risk

  2022cites this paper
• Synapses, Microglia, and Lipids in Alzheimer’s Disease

  2022cites this paper
• Biomolecular Tau condensation is linked to Tau accumulation at the nuclear envelope

  2022cites this paper
• The Role of Post-Translational Modifications on the Structure and Function of Tau Protein

  2022cites this paper
• Immunopharmacology of Alzheimer’s disease

  2022cites this paper
• Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.

  2022cites this paper
• Novel Brain-Penetrating Single Chain Antibodies Directed Against 3RTau for the Treatment of Alzheimer's Disease and Related Dementias.

  2021cites this paper
• Sex‐specific accelerated decay in time/activity‐dependent plasticity and associative memory in an animal model of Alzheimer's disease

  2021cites this paper
• β-arrestin1 promotes tauopathy by transducing GPCR signaling, disrupting microtubules and autophagy

  2021cites this paper
• Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases.

  2021cites this paper
• Transglutaminase 2 as a therapeutic target for neurological conditions

  2021cites this paper
• The NLRP3 Inflammasome in the Pathogenesis and Treatment of Alzheimer’s Disease

  2021cites this paper
• The Structure Biology of Tau and Clue for Aggregation Inhibitor Design

  2021cites this paper
• Tau oligomers accumulation sensitizes prostate cancer cells to docetaxel treatment

  2021cites this paper
• Astrocyte senescence and SASP in neurodegeneration: tau joins the loop

  2021cites this paper
• Membrane Interactions and Toxicity by Misfolded Protein Oligomers

  2021cites this paper
• Structural understanding of 5-(4-hydroxy-phenyl)-N-(2-(5-methoxy-1H-indol-3-yl)-ethyl)-3-oxopentanamide as a neuroprotectant for Alzheimer's disease.

  2021cites this paper
• Identification of the three zinc-binding sites on Tau protein

  2021cites this paper
• Tau Oligomers Neurotoxicity

  2021cites this paper
• Pyrazole Scaffold Synthesis, Functionalization, and Applications in Alzheimer’s Disease and Parkinson’s Disease Treatment (2011–2020)

  2021cites this paper
• Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease

  2021cites this paper
• Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective.

  2020cites this paper
• Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology.

  2020cites this paper
• Nuclear Transport Deficits in Tau-Related Neurodegenerative Diseases

  2020cites this paper
• A critical review of radiotracers in the positron emission tomography imaging of traumatic brain injury: FDG, tau, and amyloid imaging in mild traumatic brain injury and chronic traumatic encephalopathy

  2020cites this paper
• Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

  2020cites this paper
• Dynamic changes of autophagic flux induced by Abeta in the brain of postmortem Alzheimer’s disease patients, animal models and cell models

  2020cites this paper
• Evidence Linking Protein Misfolding to Quality Control in Progressive Neurodegenerative Diseases.

  2020cites this paper
• First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases.

  2020cites this paper
• The structure and phase of tau: from monomer to amyloid filament

  2020cites this paper
• Dual targeting of monomeric tau and α-synuclein aggregation: A new multitarget therapeutic strategy for neurodegeneration.

  2020cites this paper
• A human induced pluripotent stem cell‐derived cortical neuron human‐on‐a chip system to study Aβ42 and tau‐induced pathophysiological effects on long‐term potentiation

  2020cites this paper
• Tau and DNA Damage in Neurodegeneration

  2020cites this paper
• The role of wild-type tau in Alzheimer's disease and related tauopathies.

  2020cites this paper
• New Insights Into Drug Discovery Targeting Tau Protein

  2020cites this paper
• Alterations in Tau Metabolism in ALS and ALS-FTSD

  2020cites this paper
• Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease

  2020cites this paper
• Liquid-liquid phase separation induces pathogenic tau conformations in vitro

  2020cites this paper
• α-Synuclein and tau, two targets for dementia

  2020cites this paper
• Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies

  2019cites this paper
• A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice

  2019cites this paper
• The intra-brain distribution of brain targeting delivery systems

  2019cites this paper
• The Role of the Tau N-Terminal Phosphatase-Activating Domain and Phosphorylation at Thr175 in the Formation of Tau Cytoplasmic Inclusions

  2019cites this paper
• Effect of Melatonin on Tau aggregation and Tau-mediated cell surface morphology

  2019cites this paper
• Liquid-Liquid Phase Separation of Tau Protein in Neurobiology and Pathology.

  2019cites this paper
• The Formyl Peptide Receptor 2 Regulates Microglial Phenotype Through Immunometabolism: Implications for Alzheimer’s Disease

  2019cites this paper
• Four-repeat tauopathies.

  2019cites this paper